These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35847011)

  • 21. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression.
    Pereira VS; Joca SRL; Harvey BH; Elfving B; Wegener G
    Acta Neuropsychiatr; 2019 Oct; 31(5):258-265. PubMed ID: 31230597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal delivery of breakthrough therapeutics for the management of treatment-resistant and post-partum depression.
    Bhattaccharjee SA; Murnane KS; Banga AK
    Int J Pharm; 2020 Dec; 591():120007. PubMed ID: 33191204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Keeping up with the clinical advances: depression.
    Ragguett RM; Tamura JK; McIntyre RS
    CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The next psychoactive drugs: From imipramine to ketamine].
    Carrillo P; Petit AC; Gaillard R; Vinckier F
    Bull Acad Natl Med; 2020 Dec; 204(9):1034-1042. PubMed ID: 32963409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials.
    Majeed A; Xiong J; Teopiz KM; Ng J; Ho R; Rosenblat JD; Phan L; Cao B; McIntyre RS
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):63-74. PubMed ID: 33682569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical overview of NMDA-R antagonists and clinical practice.
    Davoudian PA; Wilkinson ST
    Adv Pharmacol; 2020; 89():103-129. PubMed ID: 32616204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
    Wang J; Jing L; Toledo-Salas JC; Xu L
    Neurosci Bull; 2015 Feb; 31(1):75-86. PubMed ID: 25488282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants?
    Frizzo ME
    Curr Ther Res Clin Exp; 2019; 91():25-32. PubMed ID: 31871505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A brief history of antidepressant drug development: from tricyclics to beyond ketamine.
    Pereira VS; Hiroaki-Sato VA
    Acta Neuropsychiatr; 2018 Dec; 30(6):307-322. PubMed ID: 29388517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel glutamatergic drugs for the treatment of mood disorders.
    Lapidus KA; Soleimani L; Murrough JW
    Neuropsychiatr Dis Treat; 2013; 9():1101-12. PubMed ID: 23976856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives].
    Javelot H
    Ann Pharm Fr; 2016 Mar; 74(2):93-118. PubMed ID: 26472602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression.
    Wang YT; Wang XL; Feng ST; Chen NH; Wang ZZ; Zhang Y
    Pharmacol Res; 2021 Sep; 171():105761. PubMed ID: 34242798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rapid-acting antidepressants-neurobiological mechanisms of action].
    Gass P; Vasilescu AN; Inta D
    Nervenarzt; 2022 Mar; 93(3):223-233. PubMed ID: 34766186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.